<SEC-DOCUMENT>0001193125-23-122442.txt : 20230427
<SEC-HEADER>0001193125-23-122442.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427164409
ACCESSION NUMBER:		0001193125-23-122442
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IN8BIO, INC.
		CENTRAL INDEX KEY:			0001740279
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				825462585
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268288
		FILM NUMBER:		23857914

	BUSINESS ADDRESS:	
		STREET 1:		EMPIRE STATE BUILDING
		STREET 2:		350 5TH AVENUE, SUITE 5330
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		(646) 600-6438

	MAIL ADDRESS:	
		STREET 1:		EMPIRE STATE BUILDING
		STREET 2:		350 5TH AVENUE, SUITE 5330
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Incysus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20180510
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d470057d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-268288</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To prospectus dated on
November&nbsp;21, 2022) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g470057g0426014037574.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to $2,949,000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement amends and supplements the information in the prospectus, dated November&nbsp;21, 2022 (the &#147;Prior Prospectus&#148;), filed
with the Securities and Exchange Commission as a part of our registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268288),</FONT> relating to the offer and sale of up to
$7,200,000 of shares of our common stock, $0.0001 par value per share, pursuant to the Controlled Equity Offering<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> (the &#147;Sales Agreement&#148;) we previously entered into with Cantor
Fitzgerald&nbsp;&amp; Co. and Truist Securities, Inc. (together, the &#147;Sales Agents&#148;). This prospectus supplement is registering the offer and sales of up to $2,949,000 of shares of our common stock, which is in addition to the offer and
sale of $5,949,000 of shares of our common stock registered on the prospectus supplement, dated April 25, 2023, all of which have been sold. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by
reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with,
the Prior Prospectus and any future amendments or supplements thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through April&nbsp;26, 2023, we have sold 5,086,088 shares of our common stock for
gross proceeds of approximately $10,772,319 in accordance with the Sales Agreement under the Prior Prospectus and the prospectus supplement, dated April 25, 2023. We are subject to General Instruction I.B.6 of Form
<FONT STYLE="white-space:nowrap">S-3,</FONT> which limits the amounts that we may sell under the registration statement of which this prospectus supplement and the Prior Prospectus are a part. After giving effect to these limitations and the current
public float of our common stock, and after giving effect to the terms of the Sales Agreement, we currently may offer and sell shares of our common stock having an aggregate offering price of up to $2,949,000 under the Sales Agreement. If our public
float increases such that we may sell additional amounts under the Sales Agreement and the registration statement of which this prospectus supplement and the Prior Prospectus are a part, we will file another prospectus supplement prior to making
additional sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Market under the trading symbol &#147;INAB.&#148; The aggregate market value of our
common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of April&nbsp;26, 2023 pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> is $41,164,605, which was calculated based on 13,721,535
shares of our common stock outstanding held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> and at a price of $3.00 per share, the closing price of our common stock on April&nbsp;24, 2023. As of the date hereof, we have offered and sold
$10,772,319 of securities pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> during the prior 12 calendar month period that ends on and includes the date hereof. As a result of the limitations of General
Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> and in accordance with the terms of the Sales Agreement, we are registering the offer and sale of shares of our common stock having an aggregate offering price of up to
$2,949,000 from time to time through or to the Sales Agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully
the risks and uncertainties described under the section titled &#147;Risk Factors&#148; on page 7 of the Prior Prospectus and in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> and any amendments thereto, which
are incorporated by reference into the Prior Prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the Prior Prospectus for a discussion
of the factors you should consider before making a decision to invest in our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any
state securities commission has approved or disapproved of these securities or determined if this prospectus or the Prior Prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Cantor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Truist Securities</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is April&nbsp;27, 2023. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g470057g0426014037574.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g470057g0426014037574.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  *(# 2(  A$! Q$!_\0
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MVMQ*ZG*R,.(QZGV]JVC2?Q3%+&Q;5.BNWS/5_#%Y:7VF-+:QRIM?RW\W[Y(
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(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
